FORM 10-Q


                       Securities and Exchange Commission
                             Washington, D. C. 20549

         (Mark One)
                  X   Quarterly Report Pursuant to Section 13 or 15(d)
                  -
                     of the Securities Exchange Act of 1934

                       For Quarter Ended: August 31, 2000
                                 ---------------
                                       OR
                  _  Transition Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                         Commission File Number: 0-14820

                                  IMMUCOR, INC.
             (Exact name of registrant as specified in its charter)


                    Georgia                                22-2408354
           (State or other jurisdiction of              (I.R.S. Employer
            incorporation or organization)              Identification No.)

          3130 Gateway Drive P.O. Box 5625 Norcross, Georgia   30091-5625
               (Address of principal executive offices)        (Zip Code)


                  Registrant's telephone number: (770) 441-2051

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                    Yes X No

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.

        As of October 3, 2000: Common Stock, $. 10 Par Value - 7,277,617





                                  IMMUCOR, INC.
              Notes to Condensed Consolidated Financial Statements
                                   (Unaudited)


                                 IMMUCOR, INC.
                      Condensed Consolidated Balance Sheets
<TABLE>
<CAPTION>

                                                                     August 31, 2000     May 31, 2000
ASSETS                                                               (Unaudited)           (Audited)
                                                                    ---------------      ---------------
<S>                                                                       <C>                  <C>

Current assets:
    Cash and cash equivalents                                          $ 2,835,238          $ 3,505,926
    Accounts receivable, net                                            22,144,030           21,726,062
    Inventories                                                         18,039,030           16,813,239
    Income taxes receivable                                              1,291,291              752,470
    Deferred income taxes                                                  914,676              902,409
    Prepaid expenses and other                                           1,955,889            1,321,363
                                                                    ---------------      ---------------
        Total current assets                                            47,180,154           45,021,469

Long-term investment, at cost                                            1,000,000            1,000,000

Property and equipment, at cost                                         25,193,887           25,196,862
    less accumulated depreciation                                       (8,268,808)          (7,720,980)
                                                                    ---------------      ---------------
                                                                        16,925,079           17,475,882

Deferred income taxes                                                    1,137,032            1,120,238

Other assets, net                                                        2,641,303            2,251,293

Deferred licensing costs, net                                            1,977,039            2,044,850

Excess of cost over net tangible assets acquired, net                   33,230,595           33,861,147
                                                                    ---------------      ---------------

                                                                     $ 104,091,202        $ 102,774,879
                                                                    ===============      ===============

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
    Current portion of borrowings
         under bank line of credit agreements                          $ 1,845,658          $ 2,952,307
    Current portion of long-term debt                                    4,163,570            4,277,598
    Current portion of capital lease obligations                           613,557              618,240
    Accounts payable                                                    10,807,346            9,442,977
    Income taxes payable                                                   107,181               74,715
    Accrued salaries and wages                                           1,186,407            1,346,874
    Deferred income taxes                                                  408,263              164,243
    Other accrued liabilities                                            4,597,670            4,276,554
                                                                    ---------------      ---------------
        Total current liabilities                                       23,729,652           23,153,508


Long-term debt, including borrowings
   under bank line of credit agreements                                  36,618,606           33,150,485
Capital lease obligations                                                1,623,558            1,664,165

Deferred income taxes                                                    2,833,912            3,062,331

Other liabilities                                                          821,862              825,592

Shareholders' equity:
    Common stock, $.10 par value                                           727,762              746,212
    Additional paid-in capital                                          15,382,541           16,848,804
    Retained earnings                                                   28,095,310           28,310,741
    Accumulated other comprehensive loss                                (5,742,001)          (4,986,959)
                                                                    ---------------      ---------------

        Total shareholders' equity                                      38,463,612           40,918,798
                                                                    ---------------      ---------------

                                                                     $ 104,091,202        $ 102,774,879
                                                                    ===============      ===============

</TABLE>


See accompanying notes.


                                  IMMUCOR, INC.
                    Condensed Consolidated Statements of Income
                                   (Unaudited)


                                                   Three Months Ended
                                              August 31,            August 31,
                                                 2000                  1999
                                           ---------------       ---------------

Net sales                                     $17,081,242          $ 18,929,967
Cost of sales                                   8,567,954             8,954,427
                                           ---------------       ---------------
Gross profit                                    8,513,288             9,975,540

Research and development                          473,025               358,688
Selling and marketing                           3,181,462             3,007,097
Distribution                                    1,427,601             1,535,270
General and administrative                      2,369,910             2,380,978
Amortization expense                              484,092               460,900
                                           ---------------       ---------------
Total operating expenses                        7,936,090             7,742,933
                                           ---------------       ---------------

Income from operations                            577,198             2,232,607

Interest income                                     3,787                 4,517
Interest expense                                 (865,715)             (649,334)
Other income                                       85,301                90,054
                                           ---------------       ---------------
Total other                                      (776,627)             (554,763)
                                           ---------------       ---------------

Income (loss) before income taxes                (199,429)            1,677,844

Income taxes                                       16,002               458,698
                                           ---------------       ---------------

Net (loss) income                              $ (215,431)          $ 1,219,146
                                           ===============       ===============

Earnings (loss) per share:

     Basic                                        $ (0.03)               $ 0.16
                                           ===============       ===============

     Diluted                                      $ (0.03)               $ 0.14
                                           ===============       ===============


Weighted average shares outstanding:

     Basic                                      7,311,801             7,604,991
                                           ===============       ===============

     Diluted                                    7,311,801             8,756,946
                                           ===============       ===============



See accompanying notes.

IMMUCOR, INC.
                 Condensed Consolidated Statements of Cash Flows
                                   (Unaudited)

<TABLE>
<CAPTION>

                                                                                   Three Months Ended
                                                                            August 31,           August 31,
                                                                               2000                 1999
                                                                          ---------------      ----------------
<S>                                                                               <C>                   <C>
OPERATING ACTIVITIES:
  Net income                                                                   ($215,431)           $1,219,146
  Adjustments to reconcile net income to
    net cash provided by operating activities:
      Depreciation                                                               792,486               535,372
      Amortization                                                               484,092               460,900
      Changes in assets and liabilities:
        Accounts receivable                                                     (417,968)              727,583
        Accounts receivable from former officer and director                           -               140,946
        Income tax receivable                                                   (538,857)              190,350
        Inventories                                                           (1,196,548)           (1,100,900)
        Other current assets                                                  (1,063,711)              373,813
        Accounts payable                                                       1,364,369            (2,033,679)
        Income taxes payable                                                      32,466               153,061
        Other current liabilities                                                155,726               (55,627)
                                                                          ---------------      ----------------

Cash (used in) provided by operating activities                                 (603,376)              610,965

INVESTING ACTIVITIES:
  Purchase of / deposits on property and equipment                              (406,203)             (339,225)
  Cash paid for acquisitions                                                           -              (112,913)
  Acquisition-related severance                                                        -               (88,961)
  Decrease in other assets                                                        (4,765)             (261,131)
                                                                          ---------------      ----------------

Cash used in investing activities                                               (410,968)             (802,230)

FINANCING ACTIVITIES:
  Payments under line of credit agreements                                      (214,194)                    -
  Borrowings of long term  debt and capitalized leases                         2,055,144                     -
  Borrowings/(payments) of notes payable                                         263,087              (883,735)
  Purchase of stock, net of exercises                                         (1,484,713)            1,782,482
                                                                          ---------------      ----------------

Cash provided by financing activities                                            619,324               898,747

EFFECT OF EXCHANGE RATE CHANGES ON CASH                                         (275,668)              482,240
                                                                          ---------------      ----------------

INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS                                (670,688)            1,189,722

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                               3,505,926             2,793,592
                                                                          ---------------      ----------------

CASH AND CASH EQUIVALENTS AT END OF PERIOD                                    $2,835,238            $3,983,314
                                                                          ===============      ================

</TABLE>


See accompanying notes.



1.     Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial  information  and the  instructions  to Form  10-Q and  Article  10 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial  statements.  However,  there  has  been  no  material  change  in the
information disclosed in the Company's annual financial statements dated May 31,
2000, except as disclosed herein. In the opinion of management,  all adjustments
(consisting  of  normal  recurring  accruals)  considered  necessary  for a fair
presentation have been included.  Operating  results for the three-month  period
ended August 31, 2000 are not necessarily  indicative of the results that may be
expected for the year ending May 31, 2001. For further information, refer to the
consolidated   financial  statements  and  footnotes  thereto  included  in  the
Company's Annual Report on Form 10-K for the year ended May 31, 2000.


2.       INVENTORIES

Inventories are stated at the lower of first-in, first-out cost or market:

                                    As of                         As of
                                August 31, 2000                May 31, 2000
                               -------------------           ------------------
Raw materials and supplies          $ 4,999,127                   $4,983,303
Work in process                       1,484,633                    1,603,117
Finished goods                       11,555,270                   10,226,819
                               -------------------           ------------------
                                    $18,039,030                  $16,813,239
                               ===================           ==================


3.     Earnings per share

The following table sets forth the computation of basic and diluted earnings per
share in accordance  with Statement of Financial  Accounting  Standards No. 128,
Earnings per Share.

<TABLE>
<CAPTION>

                                                         Three Months Ended
                                                     August 31,       August 31,
                                                        2000             1999
                                                   ---------------- ---------------

<S>                                                        <C>             <C>

Numerator for basic and diluted earnings per share:
  Income (loss) available to common shareholders        $(215,431)      $1,219,146
                                                   ================ ===============

Denominator:
  For basic earnings per share - weighted
  average basis                                          7,311,801       7,604,991

  Effect of dilutive stock options and warrants                  -       1,151,955
                                                   ---------------- ---------------
  Denominator for diluted earnings per share -
  adjusted weighted-average shares                       7,311,801       8,756,946
                                                   ================ ===============

Basic earnings (loss) per share                            $(0.03)           $0.16
                                                   ================ ===============

Diluted earnings (loss) per share                          $(0.03)           $0.14
                                                   ================ ===============
</TABLE>



<PAGE>



4.    domestic and foreign operations

Information   concerning  the  Company's  domestic  and  foreign  operations  is
summarized below (in 000s):

<TABLE>
<CAPTION>

                                                          Three Months Ended August 31, 2000
                          ----------------------------------------------------------------------------------------------------
                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                         <C>             <C>           <C>           <C>          <C>             <C>             <C>

Net sales:
 Unaffiliated customers    $10,660        $2,031        $1,415        $1,241        $1,734             -          $17,081
 Affiliates                  1,609            71             -            19            36        (1,735)               -
                          ----------    ----------    ----------    ----------    ---------     ------------    -------------
      Total                 12,269         2,102         1,415         1,260         1,770        (1,735)          17,081

Income from operations        (368)          366           177           313            89             -              577

</TABLE>
<TABLE>
<CAPTION>

                                                          Three Months Ended August 31, 1999
                          ----------------------------------------------------------------------------------------------------
                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                         <C>             <C>           <C>           <C>          <C>             <C>             <C>

Net sales:
 Unaffiliated  customers  $12,235        $2,118        $1,668        $1,082        $1,827             -         $18,930
 Affiliates                 1,521           101             -            72           380        (2,074)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    -----------
      Total                13,756         2,219         1,668         1,154         2,207        (2,074)         18,930

Income from operations      1,633           226           162           267           (47)           (8)          2,233

</TABLE>


During the three  months  ended  August 31, 2000 and 1999,  the  Company's  U.S.
operation  made net export  sales to  unaffiliated  customers  of  approximately
$1,666,000 and $1,748,000, respectively. The Company's German operation made net
export  sales to  unaffiliated  customers of $217,000 and $250,000 for the three
months  ended August 31, 2000 and 1999,  respectively.  The  Company's  Canadian
operation  made net export  sales to  unaffiliated  customers  of  $545,000  and
$531,000  for the three  months  ended  August 31, 2000 and 1999,  respectively.
Product sales to affiliates are valued at market prices.


5.       COMPREHENSIVE INCOME

The components of comprehensive  income (loss) for the three-month  period ended
August 31, 2000 and 1999 are as follows:

                                              Three Months Ended
                                      August 31,             August 31,
                                        2000                   1999
                                   -----------------      -----------------

Net income (loss)                     $ (215,431)              $ 1,219,146
Net foreign currency translation        (755,042)                  390,414
                                   -----------------      -----------------
Comprehensive income (loss)           $ (970,473)              $ 1,609,560
                                   =================      =================


Accumulated  comprehensive  loss as of  August  31,  2000  and May 31,  2000 was
($5,742,001) and ($4,986,959),  respectively. The balance consists of net losses
on  foreign  currency  translation  adjustments  and has been  disclosed  in the
shareholders' equity section of the condensed consolidated balance sheet.



<PAGE>



6.   ACCOUNTS RECEIVABLE FROM OFFICER AND DIRECTOR

On June 6, 2000, Edward L. Gallup,  President and CEO of Immucor,  Inc., entered
into a loan  agreement  with Immucor,  Inc. to borrow up to $400,000 in order to
meet margin  calls  related to loans made by  brokerage  companies.  The Company
acknowledges  that  certain  benefits  would  accrue to  Immucor,  Inc.  and its
shareholders if such margin calls were satisfied by some means other than having
those shares sold by the broker. The interest rate on the loan is LIBOR plus 1%,
which is the Company's current borrowing rate. As of August 31, 2000, the amount
owed to  Immucor,  Inc. is $298,000  and is secured by 105,000  Immucor  shares.
Additional borrowings of $60,000 were made in the second quarter, secured by the
same shares of stock.

7.   CONTINGENCIES

During the quarter ended August 31, 2000,  isolated  performance issues arose at
certain ABS2000 installations that resulted in mistypings not directly affecting
any patient transfusions.  The Company issued a safety notification,  requesting
customers  to  confirm  ABS2000  results  until the cause of the  difficulty  is
identified  and  corrected.  The Company  believes it has identified the factors
that caused the  performance  issues and has submitted  this  information to the
FDA. If the FDA concurs,  the Company will suspend the safety  notification  and
expects that customers may again use the ABS2000 without separate  verification.
The Company  cannot  predict how long it will take to resolve  these issues with
the FDA. In taking the prudent  approach to recording  revenues  under its third
party  leasing   arrangement,   the  company   deferred   instrument   sales  of
approximately $1 million in the current quarter.  These  performance  issues may
result in further  delays in customers  accepting  instruments,  and continue to
affect sales of reagents used in the instruments, and both of these factors will
adversely  impact  sales and  earnings.  In  addition,  the  Company may receive
requests for refunds on  instruments  already  placed in service or requests for
financial  concessions  attributable  to  inconveniences  associated  with these
performance  issues,  although no such requests  have been received  through the
date of this report.  A private  label leasing  company that  finances  customer
purchases of ABS2000  instruments has advised the Company that it is not willing
to provide  financing  for  additional  purchases of this  instrument  until the
performance  issues related to the ABS2000 are resolved to the  satisfaction  of
the FDA.

When the Company  acquired Gamma  Biologicals,  Inc.  ("Gamma  Biologicals")  in
October 1998, Gamma Biologicals was a party to an existing legal proceeding.  On
May 12, 1998, Gamma  Biologicals  received  notification  that a claim of patent
infringement  had  been  filed on that  date in U.S.  District  Court,  Southern
District of Florida,  Miami Division, by Micro Typing Systems, Inc. and Stiftung
fur Diagnostiche Forschung (the Foundation).  Subsequently, in February 1999 the
Company received notification that a second claim was filed in the U.S. District
Court for the  Northern  District of Georgia,  against  Immucor,  Inc. and Gamma
Biologicals for patent  infringement  on the first patent  described above and a
second patent  recently  granted to the  Foundation.  The claim alleges that the
recently  introduced Gamma ReACT Test System infringes U.S. patent No. 5,512,432
granted to the Foundation April 30, 1996 and U.S. patent No.  5,863,802  granted
to the  Foundation on January 26, 1999. The  plaintiffs  seek a preliminary  and
permanent  injunction  against  the  continued  alleged  infringement  by  Gamma
Biologicals and Immucor, and an award of treble damages, with interest and costs
and reasonable  attorney's  fees. On September 5, 2000 a third patent was issued
to the Foundation.  The plaintiffs have asserted infringement of this patent and
are seeking to add this patent to the lawsuit. The Company, in light of this new
patent, is evaluating its position.  A reserve for the lawsuit was recorded with
the acquisition of Gamma Biologicals that should provide for contingent expenses
related to the resolution of the lawsuit.

European  results  were  adversely  affected  by  the  interrupted  supply  of a
distributed  product produced by a large multinational  supplier.  The backorder
situation  escalated  in the  first  quarter  of 2001  and  reduced  sales by an
estimated  $230,000.  The Company  believes that the backorder will continue and
has entered into  discussions  with the supplier.  The Company believes that the
interruption of supply has given it a valid claim against the supplier.





                                  IMMUCOR, INC.

ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results
 of Operations.

    Any  statements   contained   herein  that  are  not  historical   fact  are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform  Act of  1995,  and  involve  risks  and  uncertainties.  All
forward-looking  statements  included in this document are based on  information
available  to the  Company  on the  date  hereof,  and the  Company  assumes  no
obligation  to update any such  forward-looking  statements.  Further  risks are
detailed in the Company's  filings with the Securities and Exchange  Commission,
including  those set forth in its Annual Report on Form 10-K for the fiscal year
ended May 31, 2000.

Financial Condition and Liquidity:

    As of August 31, 2000,  the  Company's  cash  position  totaled  $2,835,000.
During the  quarter the  Company  increased  borrowings  on  long-term  debt and
capitalized  leases  to  fund  capital  improvements  and  inventory  purchases.
Additionally, the repurchase of 184,500 shares of common stock for approximately
$1,500,000 was financed with the proceeds of an additional term loan.

     During the first  quarter,  the  Company did not achieve the Funded Debt to
EBITDA and Liquidity  ratios as specified in its loan agreement with its primary
bank.  These  covenant  calculations  deteriorated  due to the Company's  recent
reported  losses.  The Company has begun  discussions  to  restructure  the loan
covenants and debt repayment  schedule.  The bank has agreed to waive these loan
covenants  for the  next 12  months.  Management  believes  based  upon a timely
clearance  by the FDA of the  ABS2000  safety  notification  that the  Company's
current cash and cash  equivalents  balance,  internally  generated  funds,  and
amounts  available  under the lines of credit should be more than  sufficient to
support  operations for planned product  introduction and continued  improvement
and development of products during the next 12 months.  Management also believes
that should the need arise for additional  capital for other corporate  purposes
that these needs would be  available  through the  issuance of various  forms of
equity or debt.

Results of Operations:

Net sales

    Net sales for the three months ended August 31, 2000 totaled $17,081,000,  a
decrease of $1,849,000 (10%) from last year's $18,930,000. The decrease in sales
was due, in large part, to lower  instrumentation sales in the U.S following the
ABS2000 safety notification issued this quarter (see Note 7 Contingencies).  The
Company  generated  instrument  revenues of $750,000 for the quarter compared to
$1,900,000  for the same period last year.  Reagent  sales were also affected by
the  notification  that resulted in the loss of $121,000 in revenue for reagents
provided free of charge to customers  performing backup testing. The strength of
the US dollar versus the Euro had the effect of reducing reported European sales
by approximately $700,000, or 12%.

Gross profit

    As a percent of sales,  gross  profit for the three  months ended August 31,
2000 totaled 49.8%  compared to 52.7% for the same period in 1999.  The decrease
in gross profit margin was primarily caused by ABS2000  instrument  installation
costs incurred in this quarter, in advance of revenue  recognition.  The Company
anticipates recognizing revenues in future quarters after the FDA lifts the hold
on the systems.

Operating expenses

    When  compared to the prior year,  three-month  period ended August 31, 2000
research and development costs increased $114,000 due to instrument  development
initiatives for Europe.


<PAGE>


    Selling and marketing expenses for the three-month period increased $174,000
as  compared to the same period  last year.  The  Company  recorded  $155,000 in
additional expense  representing the impact of the interrupted  reagent sales on
ABS  customers  who  financed  their  instrument  purchase  through  fee per use
arrangements.

    Distribution  expenses  decreased  $108,000 for the three-month  period. The
decrease  relates to decreased  shipping  activity and lower  domestic  shipping
rates.

     General  and  administrative  expenses  and  amortization  expense  for the
three-month period remained relatively constant as compared with the same period
last year.

Interest expense

    When  compared  to the  prior  year  three-month  period,  interest  expense
increased  $216,000.  This is the result of  increased  borrowings  due to prior
acquisitions, share buyback programs and new capital leases for equipment.

Other income

    Other income  decreased for the three-month  period as compared to the prior
year due to lower foreign currency transaction gains in the current period.

Income taxes

    Income tax expense  decreased during the three month period ended August 31,
2000, as compared to the prior period,  due to the domestic  operating  loss but
was offset by taxes on income  provided in Germany and Canada as a result of the
Company's ongoing implementation of tax planning strategies.


<PAGE>




ITEM 3.  Quantitative and Qualitative Disclosures On Market Risk

There have been no material changes regarding the Company's market risk position
from the  information  provided in its Annual Report on Form 10-K for the fiscal
year ended May 31, 2000. The  quantitative  and  qualitative  disclosures  about
market risk are discussed in Item 7A- Quantitative  and Qualitative  Disclosures
About Market Risk, contained in the Company's Form 10-K.


PART 11 - OTHER INFORMATION



Item 6. Exhibits and Reports on Form 8-K.
         (a) The Company has filed the following exhibits with this report:

         27 Financial data schedule.

         (b) The  Company  did not file any reports on Form 8-K during the three
         months ended August 31, 2000.

   SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                  IMMUCOR, INC.
                                  (Registrant)



Date: October 16, 2000








/s/  Edward L. Gallup
 Edward L. Gallup, President







/s/  Steven C. Ramsey
 Steven C. Ramsey, Senior Vice President - Finance
 (Principal Accounting Officer)